Skip to main
SOLV

Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum Corporation (SOLV) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 36%
Hold 36%
Sell 0%
Strong Sell 9%

Bulls say

Solventum is well on track to achieving its 2028 LRP targets of 4-5% organic growth and 23-25% operating margin, ahead of schedule, thanks to their strong first quarter results and reaffirmed full year guidance. The company's high OMs for their Health Information Systems segment, along with the introduction of agentic AI, will likely bolster their HIS business and drive additional growth. With improved margins and potential for further portfolio optimization, this stock presents a strong investment opportunity with potential upside to estimates and a manageable level of risk for investors.

Bears say

Solventum is a healthcare company primed for growth, but there are concerns around their ability to sustain this growth with challenges in certain segments and potential headwinds in the form of SKU reductions. While their recent transformation program has shown positive results with higher-than-expected revenues and favorable gross margins, there are still uncertainties around the impact of this program on operating expenses and overall profitability. The initiation of their share repurchase program may provide some short-term benefits, but it remains to be seen if it will be enough to offset potential challenges in the future.

Solventum Corporation (SOLV) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 36% recommend Buy, 36% suggest Holding, 0% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Solventum Corporation and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Solventum Corporation (SOLV) Forecast

Analysts have given Solventum Corporation (SOLV) a Hold based on their latest research and market trends.

According to 11 analysts, Solventum Corporation (SOLV) has a Hold consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $84.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $84.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Solventum Corporation (SOLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.